Lunai Bioworks Inc. reported its results for the quarter ending December 31, 2025. The company ended the period with cash and cash equivalents of USD 0.49 million and an accumulated deficit of USD 509.44 million, with a working capital deficit of USD 19.49 million. Management highlighted that there is substantial doubt about Lunai Bioworks’ ability to continue as a going concern due to recurring losses and reliance on additional financing. During the period, Lunai Bioworks completed the acquisition of BioSymetrics Inc. and its subsidiary on April 8, 2025. Earlier, GediCube, B.V., previously acquired in 2024, filed for bankruptcy and ceased operations. Additionally, the company changed its corporate name from Renovaro Inc. to Lunai Bioworks Inc. on August 20, 2025. Management stated that future funding is expected to support ongoing obligations, product commercialization, clinical and regulatory development, and working capital needs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-000253), on February 17, 2026, and is solely responsible for the information contained therein.